NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED). Investors who purchased Medifast securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MED.
Investigation Details:
On April 29, 2024, Medifast reported its quarterly earnings and adjusted its earnings per share of $0.66, considerably lower than Wall Street estimates of $0.80 per share and much lower than the same period in the previous year. Following this news, Medifast stock dropped over 22% on April 30, 2024.
What's Next?
If you are aware of any facts relating to this investigation or purchased Medifast securities, you can assist this investigation by visiting the firm's site: bgandg.com/MED. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original
press release on accesswire.com
